Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma
作者机构:Department of OncologyCapital Medical University Affiliated Beijing Ditan HospitalBeijing 100015China
出 版 物:《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期:2024年第12卷第2期
页 面:285-292页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:Capital Health Development and Scientific Research Special Project No.2022-2-2175
主 题:Lenvatinib Sintilimab Advanced hepatocellular carcinoma Combination therapy Tumor response
摘 要:BACKGROUND Recently,combination therapy has shown a better trend towards improved tumour response and survival outcomes than monotherapy in patients with hepatocellular carcinoma(HCC).However,research on triple therapy[lenvatinib+sintilimab+transarterial chemoembolization(TACE)]as a first-line treatment for advanced HCC is *** To evaluate the safety and efficacy of triple therapy as a first-line treatment for advanced *** HCC patients with Barcelona Clinic Liver Cancer stage C treated with triple therapy were *** patients were treated with lenvatinib every day and sintilimab once every 3 ***,TACE was performed every 4-6 wk if *** primary outcome of the study was overall survival(OS).The secondary outcomes were the objective response rate(ORR),disease control rate(DCR),and incidence of adverse *** Forty HCC patients who underwent triple therapy were retrospectively analysed from January 2019 to January *** a median follow-up of 8.5 months,the 3-,6-,and 12-mo OS rates were 100%,88.5%,and 22.5%,*** ORR and DCR were 45%and 90%,*** median progressive free survival and median OS were not *** complications were observed in 76%of the patients(grade 3,15%;grade 4,2.5%).CONCLUSION Combination therapy comprising lenvatinib,sintilimab and TACE achieved promising outcomes in advanced HCC patients and had manageable effects.